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Abstract 
Background: 
Statins may have immunomodulatory effects that benefit critically ill patients. 
Therefore we retrospectively examined the association between survival and 
the prescription of statins prior to admission to an intensive care unit (ICU), or 
high dependency unit (HDU), as a result of major elective surgery, or as an 
emergency with a presumed diagnosis of sepsis. 
Methods: 
We retrospectively studied critical care patients (ICU or HDU) from a tertiary 
referral UK teaching hospital. Nottingham University Hospitals has over 2200 
beds, of which 39 are critical care beds. Over a five-year period (2000–2005) 
414 patients were identified with a presumed diagnosis of sepsis, and 672 
patients were identified with a planned ICU/HDU admission following elective 
major surgery. Patients prescribed statins prior to hospital admission were 
compared with those who were not. Demographics, past medical history, drug 
history, and Acute Physiology and Chronic Health Evaluation II (APACHE II) 
scores were examined. Univariate and multivariate analyses were applied 
using the primary endpoint of survival at five years after admission. 
Results: 
Patients prescribed statins prior to critical care admission were, on average, 
older, with higher initial APACHE II scores and more pre-existing 
comorbidities. Statins were almost invariably stopped following admission to 
critical care.	 Statin usage was not associated with significantly altered survival 
during hospital admission, or at five years, for either patients with sepsis (9% 
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v 15%, P=0.121; 73% v 84%, P=0.503 respectively), or post-operative 
patients (55% v 58%, P=0.762; 57% v 63%, P=0.390). 
Conclusions: 
Prior statin usage was not associated with improved or worsening outcomes 
in patients admitted to critical care after elective surgical cases or with a 
presumed diagnosis of sepsis. 
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Introduction 
Statins (3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors) are a 
widely prescribed class of drugs. While primarily intended to treat 
hypercholesterolaemia, statins may have other relevant therapeutic 
properties, independent of lipid-lowering effects.1-3 For example, investigators 
have suggested that statins may have pleiotropic vascular endothelial effects 
that are immunomodulatory, anti-inflammatory, or antithrombotic. 4-8 As such, 
studies have sought to establish if there is an association between statin-
usage and outcomes following critical illness: such as infection, pneumonia, 
acute respiratory distress syndrome, and traumatic brain injury or stroke.9-16 
Studies have also examined the putative link between the prior statin use and 
any reduction in the morbidity and mortality from major elective surgery.17,18 
Despite widespread interest, there is still confusion regarding whether 
prescribing statins before admission to an intensive care unit (ICU), or high 
dependency unit (HDU), is associated with any subsequent increase or 
decrease in survival.  For example, prior statin usage has been associated 
with increased mortality for patients who acquired infections while in ICU, but 
associated with decreased mortality in patients with multi-organ 
dysfunction.19,20 Moreover, most studies have only concentrated on short-term 
outcomes. As a result, it is also unclear whether statins should be continued 
or discontinued during critical illness. This study will further explore the 
association between prior use of statins and outcome in i) patients admitted to 
ICU or HDU as an emergency with presumed sepsis, and ii) patients 
electively admitted to ICU or HDU after major surgery.  
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Methods 
Nottingham University Hospital (NUH) consists of the Queens Medical 
Centre and Nottingham City Hospital, and is located in the Midlands of 
England. These two sites provide critical care support to a population of 
between one and four million, depending on the condition being treated.  
Ethics approval was obtained from to perform a retrospective chart 
review of all adult patients admitted to NUH between January 1st 2000 and 
December 31st 2005 (inclusive). At that time there were 21 multidisciplinary 
ICU beds and 18 HDU beds. 
Patients were identified using three databases which encompassed 
different critical care areas and were continuously maintained: the Intensive 
Care National Audit and Research Centre (ICNARC), and two locally 
maintained Microsoft Access™ databases. Two cohorts were identified: i) 
those with a presumed diagnosis of sepsis, and ii) those with elective 
admission following major surgery.  
Any patient with unavailable or incomplete notes was excluded. Post-
operative patients were excluded if their admission followed surgical or 
anaesthetic complications, or if surgery was otherwise non-elective (e.g., 
surgery for abscess drainage or perforated viscus). Only the first admission 
was counted for those with multiple admissions. If patients were deemed 
(from chart review) to be both septic and elective post-operative they were 
only included once, and in the first cohort to which they presented.  
Chart review was performed (by MB, IJ, JC-S, KG, CL, and AA) to 
confirm demographics, reason for ICU/HDU admission, and any chronic 
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disease or prescription medication prior to hospital admission. Statin usage 
was recorded along with that of other cardiovascular medications: including 
angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor 
antagonists (ARAs), long-acting nitrates, beta-blockers, and calcium channel 
antagonists (CCAs). Given the retrospective nature of the study, it was not 
possible to identify the indication, dosing, length of use, or compliance 
associated with any individual medication; nor was it possible to determine the 
efficacy of pre-admission medication usage. 
Patients were defined as having a significant comorbidity if it was 
recorded in the case-notes under the section “past medical history” on 
admission to hospital or on admission to ICU. Comorbidities recorded 
included ischemic heart disease (pre-defined as any history of angina, heart 
failure, previous myocardial infarctions or ischemic heart disease), other 
vascular disease (including cerebrovascular disease and peripheral vascular 
disease), diabetes (both non-insulin dependent and insulin-dependent 
diabetes), and chronic renal insufficiency (defined as those with chronic 
kidney disease of stage-3 or worse: estimated glomerular filtration rate <60 
ml/min/1.73 m2). Other admission variables recorded included: age, gender 
and Acute Physiology and Chronic Health Evaluation II (APACHE II) score. 
Having retrospectively identified patients, both cohorts were passively-
followed in a prospective manner over the next nine years by recording 
hospital attendances. This made it possible to calculate survival at five-years 
after ICU admission (the primary outcome) for the majority of patients. 
Secondary outcomes were survival to ICU-discharge, survival to hospital-
discharge, length of ICU stay (ICU-LOS), presence of three or more systemic 
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inflammatory response syndrome (SIRS) criteria, and evidence of 
cardiovascular instability (defined as the need for inotropic or vasopressor 
support within the first twenty-four hours of admission). 
Baseline characteristics were compared between cohorts, with Chi-
squared analysis of nominal data and independent sample t-tests for 
continuous data (e.g. age and APACHE II scores). Univariate analysis was 
also used to compare the raw outcomes for comparing prior statin usage and 
no prior statin usage. Binary logistic regression was also performed to 
calculate odds ratios adjusted for potential confounders including: age, 
gender, APACHE II score, presence of premorbid diabetes or cardiovascular 
illness, and premorbid use of other cardiovascularly-active medications. 
Kaplan Meier estimates of five-year survival were calculated and analysed 
using log rank tests. Analyses were carried out using SPSS (IBM SPSS 
Statistics for Macintosh, Version 14.0, Chicago) and statistical significance 
was deemed as a P-value less than 0.05. 
 
Results 
Approximately 6590 patients were admitted to the critical care units 
between January 1st 2000 and December 31st 2005. (Figure 1). Of these, a 
cohort of 414 patients was admitted for presumed sepsis, and 672 patients 
were admitted following major elective surgery. All study patients had their 
statin usage interrupted for at least some period of their admission to a critical 
care environment. 
Patients who had been prescribed statins prior to admission were more 
likely to be older, and have marginally-higher APACHE II scores (Table 1). 
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Statins users also had a higher incidence of related comorbidities (diabetes, 
vascular disease, ischaemic heart disease), and co-prescribed cardiovascular 
medications. In the surgical cohort, statins users were more likely to have had 
vascular surgery prior to elective admission. Within both cohorts 
approximately 13% of patients had been prescribed statins, with simvastatin 
and atorvastatin being the most widely used: these two medications 
accounted for approximately 80% of all statins. 
Data analysis revealed few differences in outcomes when comparing 
patients prescribed statins compared with those not prescribed statins (Table 
2). There was no difference in in-hospital mortality between patients not 
previously prescribed statins and those who had been taking statins (9% v 
15%, P=0.121, for post-operative patients; 55% v 58%, P=0.762, for patients 
with presumed sepsis); nor was there any difference in five year survival (57% 
v 63%, P=0.390; 73% v 84%, P=0.503). ICU-LOS was also unaffected. Only 
ICU mortality was statistically different between the two groups in the cohort 
of post-operative patients (where absolute numbers were small). 
When comparing factors associated with inflammation or shock, the 
only statistically significant finding was that post-operative patients who had 
used statins were more likely to require inotropes (53% of patients in this 
group were prescribed adrenalin, noradrenaline or dopamine, compared with 
38% of patients who had no prior statin usage, P=0.007). 
Odds ratios were calculated for five-year survival, taking into account 
potential confounders (Table 3). Increased age, APACHE II score at ICU 
admission, and admissions following cancer surgery were all associated with 
increased five-year mortality. For those admitted non-electively with presumed 
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sepsis, the presence of vascular disease or ischaemic heart disease was 
associated with increased five-year mortality (P=0.035 and P=0.036 
respectively). There was no statistically significant difference in Kaplan Meier 
estimates of five-year survival in either cohort when comparing patients 
prescribed statins versus those not prescribed statins (Figures 2 and 3). 
An analysis of the crude mortality associated with different types of 
statin revealed a potential difference in survival (Table 4). Simvastatin was 
associated with worse hospital survival when compared with patients not 
prescribed statins (or prescribed atorvastatin). This association was only 
found in patients admitted with sepsis. 
 
Discussion 
We found little or no evidence of any association between statin usage 
and improved survival. This was true in the short-term (during ICU stay); the 
medium term (during hospital stay); the longer term (up to 5 years); and 
regardless of whether patients were admitted as an emergency (for presumed 
sepsis) or electively (after major surgery).  
Following sepsis, previous studies have intimated that pre-existing 
statin therapy may reduce cytokine levels (specifically TNF-alpha and 
interleukin-6); may protect against progression from bacteraemia to severe 
sepsis; may mitigate the need for ICU admission; and may decrease overall 
mortality.21-26 Studies have also reported a reduction in attributable mortality 
from 20% to 3% (P = 0.010).9 In contrast, our five-year study found no 
associated mortality-benefit between sepsis-survival and pre-prescription of a 
statin.  
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Studies have also reported an association between prior statin use and 
lower morbidity and mortality after cardiac surgery, non-cardiac vascular 
surgery, and other non-cardiac surgery.17-18,27-28 Again, this was not 
duplicated in our study which found no survival advantage with a statin. Our 
goal was to investigate longer-term survival following major surgery in patients 
likely to have inflammation (as defined by the SIRS criteria), but not caused 
by sepsis.  
Our study has many limitations that reduce the generalizability of our 
conclusions. These include: the retrospective nature, reliance upon chart 
records and presumptive diagnoses from a single centre; and the loss to 
follow up of twelve percent of patients. We did not confirm (or compare) 
patient’s statin dose, or duration of therapy, or pre-admission compliance. Nor 
did we confirm any effect of statins in lowering serum-lipids or specific 
inflammatory markers. We also did not establish whether statins were 
continued (or started) after ICU-to-ward discharge, or after hospital-discharge. 
Some patients were lost to follow up, most notably after major elective 
surgery. In 23 cases we know that the patients moved to another location. For 
the remainder all that is known is that after finishing attending follow-up clinics 
these patients did not require any further hospitalisation at our institution over 
the subsequent nine years. Some patients may have died in the community, 
without requiring hospital admission; or may have been admitted to other 
hospitals.  
Also, although we strived to control for likely confounders, there could 
be others: this includes treating all sepsis as if it is a homogeneous disease. 
Despite our aforementioned limitations, we also found no significant 
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association between statins and crude approximations of inflammation (three 
or more SIRS criteria) 
Age, APACHE II score, and the presence of co-morbidities did 
negatively affect survival, as has been shown in other studies. Yet statin 
usage – despite being associated with older age, increased numbers of 
comorbidities, and increased APACHE II scores – did not alter outcome. The 
possibility remains that statins might protect against the development of 
sepsis or inflammation, but that any gain is, in the long run, offset by age or 
pre-existing illness.  
Alternatively, perhaps patients receive a pre-ICU benefit thus avoiding 
ICU admission, or patients who are sick enough to need ICU patients have 
progressed beyond where statins could help. Our post-operative patients, who 
were not obviously septic but are known to be at risk, also did not 
demonstrate a benefit associated with statins. The counter argument could be 
that post-operative (non-septic) patients have too small an inflammatory 
response for statins to exert any effect. 
In fact, post-operative patients appeared to be more likely die during 
their ICU stay if they had previously been prescribed statins (9% vs 3%, 
P=0.021; Table 2). Assuming this result to be a “true” one, the argument could 
be made that statin usage is harmful, or that it acts as a surrogate marker for 
high-risk patient groups (in which case any beneficial effect of statins could be 
masked by the risk of pre-existing illness). Equally, it is likely that a note of 
caution is required when interpreting this particular finding: the absolute 
numbers were small, and the increased mortality was not sustained to 
hospital discharge. 
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Establishing the role of statins in ICU patients may be further 
complicated by ICU patient heterogeneity, especially when compared to 
cardiac patients (all of whom will presumably have vascular disease) or those 
with isolated lipid abnormalities (versus ICU patients who often have multi-
system disease).  
Pragmatically, one could argue that this study supports the conclusion 
that prior statin use does not seem to have a negative impact on long-term 
outcomes after admission to ICU. It has also been suggested that abrupt 
discontinuation of statins is associated with rapid loss of any inflammatory or 
endothelial benefit, and that there might be increased cardiac myonecrosis if 
statins are discontinued after major vascular surgery.29-33 Accordingly, over 
time, a body of opinion has developed recommending that statins should be 
continued (where possible) upon ICU admission — a practice now adopted at 
NUH.34-35 
We performed a sub-analysis, comparing the crude outcome data 
associated with different statins. Although we identified a potential increase in 
mortality associated with simvastatin in our cohort of septic patients, this was 
not replicated in post-operative patients. This should encourage further study, 
though we are mindful that statistical error can rise as sample size decreases. 
Accordingly, the numbers of patients prescribed fluvastatin, pravastatin and 
rosuvastatin were too small to perform meaningful subanalysis. Nevertheless, 
there may be heterogeneity amongst statins.36 It remains unclear whether, 
unlike their lipid lowering effects, any putative pleiotropic effects belong to the 
entire class of statins or not; and how critical illness affects each agent’s 
Statins & ICU 5 yr survival MBeed 18/12/15 Page 13 of 26 
pharmacokinetics and pharmacodynamics.37-39 In short, much work remains 
to be done. 
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Figure 1: Flowchart of numbers of patients screened and identified at 
each stage of data collection. 
 
Total number of patients screened 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Estimated from average yearly admissions over the time period as exact 
figure not available. 
 
  
Total number of admissions 
n=6590* 
Eligible patients identified 
n=1101 
Casenotes incomplete or 
unavailable for review 
n=15 
Cohort 2 
Patients admitted with a 
presumed diagnosis of sepsis 
n=414 
Cohort 1 
Patients admitted after 
major elective surgery 
n=672 
Elective patients where 
outcome at 5 years could 
be confirmed 
n=576 
Sepsis patients where 
outcome at 5 years could be 
confirmed 
n=382 
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Figure 2: Kaplan Meier estimates of five year survival of patients 
admitted to intensive care after major elective surgery, comparing those 
known to have been prescribed statins prior to admission with those not 
prescribed statins 
 
 
 
Log rank test significance p=0.302 			 	
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Figure 3: Kaplan Meier estimates of five year survival of patients 
admitted to intensive care with a diagnosis of presumed sepsis, 
comparing those known to have been prescribed statins prior to 
admission with those not prescribed statins 
 
 
 
Log rank test significance p=0.093 		
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Table 1: Baseline characteristics of patients stratified by prior statin 
usage 
 
 Post-operative patients, n=672 
 No prior statins (n=584) Prior statins (n=88) P-value* 
Age, mean (SD) 61.6 (15.6) 67.7 (13.1) 0.001 
Male gender, n (%) 366 (63) 66 (75) 0.024 
APACHE II score, mean (SD) 13.2 (5.1) 14.5 (6.4) 0.029 
Other comorbidities and medication usage   
Ischaemic heart disease, n (%) 56 (10) 53 (60) <0.005 
Other vascular disease, n (%) 65 (11) 33 (38) <0.005 
Diabetes, n (%) 33 (6) 22 (25) <0.005 
ACE inhibitors / ARAs, n (%) 57 (10) 41 (47) <0.005 
Ca2+ channel antagonists, n (%) 58 (10) 17 (19) 0.017 
Beta-blockers, n (%) 72 (12) 28 (32) <0.005 
Nitrates, n (%) 10 (2) 10 (11) <0.005 
Type of surgery    
Oesophagectomy, n (%) 210 (36) 28 (32) 0.476 
Hepato-biliary/pancreatic, n (%) 66 (11) 6 (7) 0.267 
Vascular, n (%) 44 (8) 24 (27) <0.005 
Neurosurgery, n (%) 33 (6) 2 (2) 0.299 
Type of statin     
Simvastatin, n (%)  37 (42)  
Atorvastatin, n (%)  30 (34)  
Other statin, n (%)  21 (24)  
  
 Patients with presumed sepsis, n=414 
 No prior statins (n=364) Prior statins (n=50)  
Age, mean (SD) 60.0 (16.8) 69.6 (8.1) <0.005 
Male gender, n (%) 199 (55) 28 (56) 0.881 
APACHE II score, mean (SD) 21.6 (8.1) 23.3 (8.6) 0.168 
Other comorbidities and medication usage   
Ischaemic heart disease, n (%) 44 (12) 24 (48) <0.005 
Other vascular disease, n (%) 26 (7) 15 (30) <0.005 
Diabetes, n (%) 26 (7) 20 (40) <0.005 
ACE inhibitors / ARAs, n (%) 38 (10) 22 (44) <0.005 
Ca2+ channel antagonists, n (%) 23 (6) 16 (32) <0.005 
Beta-blockers, n (%) 32 (9) 13 (26) 0.001 
Nitrates, n (%) 5 (1) 6 (12) 0.001 
Type of statin   
Simvastatin, n (%)  23 (46)  
Atorvastatin, n (%)  22 (44)  
Other statin, n (%)  5 (10)  
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Table 2: Crude outcome data stratified by statin usage 
 
 
 Post-operative patients, n=672 
 No prior statins (n=584) Prior statins (n=88) P-value* 
Died in ICU, n (%) 20 (3) 8 (9) 0.021 
Died in hospital, n (%) 53 (9) 13 (15) 0.121 
Median ICU stay, days (range) 2 (0-30) 2 (1-20) 0.517 
Inotropes prescribed within 
24hours of admission, n (%) 221 (38) 47 (53) 0.007 
Presence of SIRS criteria**, n (%) 276 (49) 40 (46) 0.567 
Died within 5 years, n (%) 286 (57) [n=498] 49 (63) [n=78] 0.390 
  
 Patients with presumed sepsis, n=414 
 No prior statins (n=364) Prior statins (n=50)  
Died in ICU, n (%) 159 (44) 24 (48) 0.649 
Died in hospital, n (%) 197 (55) 29 (58) 0.762 
Median ICU stay, days (range) 4 (1-31) 3 (1-31) 0.203 
Presenting in shock, n (%) 326 (90) 43 (86) 0.466 
Inotropes prescribed within 
24hours of admission, n (%) 293 (81) 40 (80) 0.849 
Presence of SIRS criteria**, n (%) 321 (91) 44 (90) 0.503 
Died within 5 years, n (%) 247(73) [n=339] 36(84) [n=43] 0.142 
 
*P-values are for chi-squared tests except length of ICU stay where Mann-
Whitney U-test was used 
**Modified SIRS criteria ( ≥ 3 variables) was used 
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Table 3: Adjusted odds ratio for post-operative patients and patients 
presumed to have sepsis. 
 
 
 Five year mortality for all patients 
 Post-operative patients, 
n=576 
Patients with presumed 
sepsis, n=382 
 Adjusted odds ratio P-value Adjusted odds ratio P-value 
Age 1.02 - 1.05 <0.005 1.02 - 1.06 <0.005 
Male gender 0.71 - 1.51 0.866 0.77 - 2.19 0.323 
APACHE II score 1.00 - 1.09 0.017 1.05 - 1.13 <0.005 
Other comorbidities and medication usage 
Ischaemic heart disease 0.59 - 1.94 0.825 0.09 - 0.93 0.035 
Other vascular disease 0.80 - 2.26 0.266 0.24 - 1.723 0.036 
Diabetes 0.28 - 1.09 0.090 0.96 - 5.81 0.060 
ACE inhibitors / ARAs 0.66 - 1.99 0.623 0.39 - 2.29 0.896 
Ca2+ channel 
antagonists 
0.43 - 1.43 0.428 0.39 - 3.16 0.845 
Beta-blockers 0.80 - 2.20 0.272 0.21 - 1.68 0.586 
Nitrates 0.50 - 3.81 0.531 0.16 - 18.52 0.660 
Cancer surgery 0.30 - 0.66 <0.005 - - 
Statin usage 0.46 - 1.59 0.630 0.31 - 2.87 0.917 
     
 
Cox & Snell R2 = 0.178 
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Table 4: Crude survival data stratified by type of statin 
 
 
Post-operative patients 
 Hospital mortality 
(n=672) 
 
P-value* 
5 year mortality 
(n=576) 
 
P-value* 
No statins, n (%) 53 (9)  286 (57)  
Atorvastatin, n (%) 3 (12) 0.735 14 (56) 0.999 
Simvastatin, n (%) 7 (19) 0.096 25 (69) 0.167 
Other statins, n (%) 3 (18) 0.407 10 (59) 0.999 
     
Patients with presumed sepsis 
 Hospital mortality 
(n=414) 
 
P-value* 
5 year mortality 
(n=382) 
 
P-value* 
No statins, n (%) 197 (54)  247 (73)  
Atorvastatin, n (%) 9 (50) 0.473 12 (67) 0.591 
Simvastatin, n (%) 18 (86) 0.005 20 (95) 0.02 
Other statins, n (%) 2 (50) 0.999 4 (100) 0.577 
 
 
*P-values are for chi-squared tests with Fisher’s exact test 
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